Summary Serum CA 125 regression after cytoreductive surgery and during the first three courses of chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors.
The cancer antigen CA 125 is an established serum tumour marker for monitoring of ovarian cancer patients. In most patients, CA 125 serum levels correlate well with the clinical course of the disease during therapy (Kenemans et al., 1988; Jacobs & Bast, 1989) . Current treatment results are reached at the expense of extensive cytoreductive surgery followed by intensive, prolonged poly-chemotherapy. Usually, this is continued until second-look surgery unless progressive disease becomes evident. Cytotoxic therapy is often accompanied by severe side effects. It is of major importance that nonresponders to chemotherapy are identified early in the course of treatment. This allows a timely change in the cytostatic agents used, whereas the use of further ineffective toxic chemotherapy can be avoided.
In recent studies, attempts have been made to predict on the basis of serial CA 125 levels the effect of first-line chemotherapy as defined by time to tumour progression or overall survival. Canney et al. first noted that in patients with regressing CA 125 serum levels, a shorter CA 125 half-life correlated with a good clinical response to therapy (Canney et al., 1984) . Observations by Lavin et al., indicated that a failure of CA 125 to regress to normal after three courses of chemotherapy, predicted persistent disease after completion of therapy (Lavin et al., 1987) . In addition, the percentage change after one course of chemotherapy was reported to be related to progression-free survival (Rustin et al., 1989) although this was not confirmed by others (Redman et al., 1990) .
Van der Burg et al. first reported a CA 125 half-life of more than 20 days to be associated with a shorter median time to progression (Van der Burg et al., 1988) . Recently, CA 125 half-lives were computed using an exponential regression model utilising all CA 125 measurements available between surgery and either CA 125 normalisation, or the lowest CA 125 value obtained. Employing this model, promising results in predicting therapy efficacy have been reported (Buller et al., 1991) .
To further evaluate the role of CA 125 regression early in the course of therapy and to test the above mentioned models for calculating the CA 125 half-life, a retrospective study was carried out using CA 125 measurements in the interval between cytoreductive surgery and the completion of three courses of chemotherapy. The predictive significance of a CA 125 normalisation and that of the calculated CA 125 half-life value were studied in relation to survival and in combination with other known risk factors in ovarian cancer.
Materials and methods

Patients
Sixty patients with ovarian cancer were included in the present study (median age: 61 years, range: 32-81). All patients underwent primary cytoreductive surgery between July 1984 and December 1990. Surgery was performed at the Free University Hospital Amsterdam or at the University Hospital of Nijmegen, the Netherlands. Staging was performed according to FIGO recommendations (Kottmeier, 1976 A total of 346 serum samples were collected from 60 patients. CA 125 levels were measured before surgery (n = 60), between surgery and the first course of chemotherapy (n = 141) and after course I (n = 50), after course II (n = 44) and after course III (n = 51) respectively. CA 125 was assayed using the immunoradiometric assay CA 125 provided by Centocor (Malvern, PA, USA) according to the manufacturer's instructions (Bast et al., 1983) . The 35 U ml' level was used as cut-off value.
Calculations of the CA 125 half-life CA 125 half-lives were calculated using the formula as described by Van der Burg et al., 1988 : tl/2 = dt/21og (CA 125-1/CA 125-2); in which CA 125-1 is the CA 125 value before chemotherapy (II) and CA 125-2 is the first normal CA 125 value or the lowest CA 125 value if CA 125 did not normalise within 3 months after the start of chemotherapy (III). This half-life was named tl/2 (a).
In addition, using the same formula, CA 125 half-lives were calculated using pre-surgery levels as a baseline value (I) and taking as the second sample either the first normal CA 125 value or the lowest CA 125 value when no normalisation occurred within 3 months from the start of therapy (III). In this case, surgery was considered as the start of therapy and the estimated half-life calculated this way is referred to as tl/2 (b). The CA 125 half-life calculated using again the pre-surgery level as a baseline (I) and taking the prechemotherapy CA 125 level as the second sample (II) is referred to as tl/2 (c).
Finally, the CA 125 half-life was calculated using the exponential regression model according to Buller et al., 1991 based on the formula: CA 125 = exp. [i-s x (days after surgery)]; where i is the y axis intercept and s is the slope of the regression curve. The half-life is calculated from the slope using the formula: tl/2 = 0.693/s. In this regression analysis, pre-operative as well as all post-operative CA 125 levels were included until either normalisation or until the lowest CA 125 value had been reached if an increase occurred during chemotherapy. This half-life is referred to as tl/2 (d). KaplanMeier. Differences between two curves were tested using the log rank test. Survival time was truncated at 3 years because of the lack of follow-up data after this period. Two year survival rates were compared for each prognostic variable and the Fisher exact test was used to test differences between groups. To evaluate adjusted prognostic factors, a multiple regression analysis was performed using the Cox proportional hazards model (Dixon, 1983 Figure 3 ).
For each type of half-life calculation the prognostic value was also tested at additional cut-off levels of 10, 30 and 40 days. No better correlation with survival was observed using these cut-off levels (data not shown). significant prognostic variables as covariates in a Cox Proportional Hazards model. Stage of disease provided the best correlation with overall survival (P = 0.006). Of all other variables which showed a significant correlation with survival in the univariate analysis (Table II) , only tl/2 (d) could further improve survival correlation (P = 0.04). Thus, the calculated half-life according to the formula of Buller et al. using a cut-off of 20 days, was the only additional independent prognostic factor for survival in addition to FIGO stage.
In this study the prognostic value of early CA 125 regression following cytoreductive surgery and during first-line chemotherapy in ovarian cancer was assessed. Patients with stage III-IV ovarian cancer and a CA 125 normalisation after three courses of chemotherapy and those with a CA 125 half-life < 20 days had a significant better prognosis than patients who had not normalised after the third course or who had a CA 125 half-life>20 days. This is in accordance with previous reports (Lavin et al., 1987; Sevelda et al., 1989; Mogensen et al., 1990; Redman et al., 1990) .
In one study, the risk of dying of ovarian cancer for those patients with elevated CA 125 levels 3 months after surgery was three times as high as for patients whose serum levels had normalised (Sevelda et al., 1989) . However, a CA 125 normalisation remains of limited predictive value for the definitive chance of cure, as Mogensen et al. reported that 23 out of 47 patients with residual tumour at second-look had shown normal CA 125 serum levels after three courses of chemotherapy (Mogensen et al., 1990) . In the present study, 5 out of 17 stage III-IV patients died within 2 years after primary surgery despite a CA 125 normalisation after three courses of chemotherapy.
Mogensen subdivided patients according to absolute CA 125 serum levels after three courses of chemotherapy. Significantly different survival rates were observed for patients with CA 125 levels,lOUml1', 11-l0OUmlh' and > 100 U ml-' independently of other prognostic factors (Mogensen, 1992) . However, even in the group with CA 125 values < 10 U ml-', 50% died within 5 years after surgery. In his study, Mogensen used both the Abbott RIA and Abbott EIA. Reported CA 125 levels will be different when using the original Centocor CA 125 RIA since there are considerable (Yedema et al., 1992a) .
As shown recently, the time interval within which mean CA 125 serum levels differ significantly between therapy responders and non-responders can be as short as 1 to 4 weeks after surgery (Cruickshank et al., 1992) . However, within the group of patients with residual disease> 2 cm, a discrimination between responders and non-responders could not be made that early.
Using pre-chemotherapy CA 125 baseline levels, CA 125 half-life values have been reported to be inversely related to the duration of progression free survival and overall survival (Van der Burg et al., 1988; Hawkins et al., 1989; Hogberg & Kagedal, 1990 (Yedema et al., 1993 (Hawkins et al., 1989 , Hogberg & Kagedal, 1990 ; Van der Burg et al., 1988) . Furthermore, patient selection may explain these differences. Once enrolled in the present study, no patients were excluded while others only included patients showing a favourable response to therapy (Hawkins et al., 1989; Hogberg & Kagedal, 1990) thus excluding patients with progressive or stable disease. While we studied only stage III-IV patients, Van der Burg included a large portion of stage I-TI patients in her study group (Van der Burg et al., 1988) . These patients will have a low progression rate and prolonged survival and CA 125 is expected to normalise within a short time once chemotherapy is initiated. Consequently, patients with early stage I-IT disease will be over-represented in the short half-life group.
We found a significant correlation between CA 125 halflife and survival only if pre-surgery levels were taken as a baseline value. These data are in agreement with those of others using pre-surgery baseline values (Hunter et al., 1990; Willemse et al., 1991) .
The best correlation between the CA 125 half-life and survival was provided using the exponential regression model of Buller et al. (Buller et al., 1991 siveness to chemotherapy. In our multiple regression analysis this factor was, in addition to stage of disease, the only independent prognostic variable in predicting survival. Thus, our data show that this model can be used as an independent predictor of survival. The half-life of CA 125 after complete debulking is a particular point of interest. Canney et al. found a CA 125 half-life of 4.8 days based on one single observation (Canney et al., 1984) . Buller et al. reported a mean serum half-life of 10.8 days (Buller et al., 1991) in their study population, which included a substantial portion of completely resected stage III-IV patients, some of whom might suffer from early tumour recurrence. This occurred in two stage III patients from the present series at 9 and 18 months after complete cytoreductive surgery. All stage I-II patients in the present study who underwent complete cytoreductive surgery were without evidence of disease in the follow-up period (median 29 months, range 8-85). In these 12 patients, the mean CA 125 half-life tl/2 (d) according to Buller was 9.8 days. At a cut-off of 16.5 days (mean + 2SD) univariate analysis showed a significant correlation with survival, while in a multivariate model, no independent prognostic value could be found (P = 0.09). We believe that CA 125 regression in stage I-II patients deserves further attention to obtain an estimate of the ideal CA 125 regression curve which could serve as a reference for patients with advanced disease.
In the present study there were short term and long term survivors in respectively the short CA 125 half-life (,<20 days) and the long CA 125 half-life group (>20 days) (Figure 4) . Also in previous studies based on absolute CA 125 values, overlapping values between good and poor responders were frequently found. The CA 125 half-life based on the exponential regression model according to Buller was the only variable with a significant prognostic value other than stage in the multivariate analysis. Whether or not the CA 125 half-life based on serial measurements early during therapy is a better discriminator between good and poor responders than single CA 125 measurements before therapy and after three courses remains to be elucidated. A large scale multi-centre study might give the answer which CA 125 response at what stage during therapy provides the best estimation of the survival time to be expected.
